Loading
A phase 2 trial of Sipuleucel-T in prostate cancer, run by Dendreon, now recruiting.
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T is a phase 2 interventional study registered as NCT06134232 by Dendreon, with 400 participants planned, started 2023-10-02 and due to reach its primary completion in 2031-12-31. Interventions recorded: Sipuleucel-T Injection. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dendreon, Sipuleucel-T, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Sipuleucel-T, Prostate cancer.
Shares Sipuleucel-T, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/